Lead Product(s): Antibody-based therapy
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $121.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration March 08, 2021
The research collaboration and license agreement that will leverage Biolojic's AI-based multibody platform to discover and develop a potential novel antibody-based therapy for the treatment of diabetes.